Collaborative online learning for trainees interested in hepatology | Founded by @hershshroff @LizzieAbyMD @paritapatelmd @adam_c_winters @alexsvogel | #MedEd
Joined April 2020
- Tweets1.9K
- Following274
- Followers10.9K
- Likes2.7K
Pinned Tweet
Excited to introduce the 2026–2027 Liver Fellow Network Leads! 🎉
Driven by a shared commitment to hepatology education and collaboration, we are looking forward to a year of learning and advancing our global liver community together 🌍
#LFN #LiverTwitter #MedEd @AASLDtweets
⏰ The deadline is tomorrow ‼️#HepMadness2026
16 themes. One champion. 🏆
Have you made your picks yet? Submit your bracket here: tourneytopia.com/aasld/hepma…
🏀 Next up: Disease Overlap in Chronic Liver Disease
@sanapirzadaMD explores how overlapping liver diseases affect outcomes, recompensation, and the performance of fibrosis tests.
Could this theme change how we assess risk? 👇 #HepMadness2026
5/5 Does disease overlap earn a place in your next round—or take the title? 🏆
Submit your bracket by Oct 31:
tourneytopia.com/aasld/hepma…
@LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
4/5 The challenge:
These associations don’t prove causation. MetALD was not an independent mortality predictor, and fibrosis tests performed differently across groups.
One diagnosis—or one testing pathway—may not capture the full picture.
3/5 The evidence:
• 44 studies, 19,898 patients: steatosis prevalence was 27% in AIH.
• 194 patients: recompensation was 3% in MetALD vs 18% in ALD.
• 893 patients: FIB-4 AUC was 0.77 in MetALD vs 0.54 in ALD.
2/5 Why it’s a title contender:
Liver diseases often coexist.
Steatosis in autoimmune liver disease and combined metabolic–alcohol-related disease can affect prognosis. Recognizing this overlap could help us assess patients more accurately.
🏀 Next up: Integrated Chronic Liver Disease Care
@kush_m_patel96 explores multidisciplinary MASH clinics and integrated hepatology–addiction care.
Can bringing care together improve liver outcomes?
Thread 👇 #HepMadness2026
5/5 Does integrated care earn a place in your next round—or take the title? 🏆
Submit your bracket by Oct 31:
tourneytopia.com/aasld/hepma…
@LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
4/5 The challenge:
The clinic studies lacked comparator groups, and patients who declined ALD care were sicker.
The inpatient study compared different hospitals and time periods. Controlled studies are needed to separate the care model’s effect from patient engagement.
3/5 The evidence:
• MASH clinic: 26 with 6-month data; 26% lost ≥5% body weight.
• Outpatient ALD care: fewer ED visits (IRR 0.64).
• Inpatient hepatology + addiction care: fewer liver-related events (aHR 0.50) and lower 30-day alcohol readmission (18% vs 32%).
2/5 Why it’s a title contender:
Liver disease rarely exists in isolation.
This theme brings metabolic health, alcohol use treatment, and hepatology together—with studies examining liver markers, emergency visits, and future liver-related events.
Liver Fellow Network retweeted
⏰ Only 3 days until #HepMadness2026 brackets lock!
16 themes. One champion. 🏆
Have you made your picks yet? Submit your bracket here: tourneytopia.com/aasld/hepma…
🏀 Next up: Role of Thyroid Hormone in Hepato-Endocrinology
Rachel Thompson explores the thyroid–liver connection, from lipid metabolism and insulin sensitivity to HCC risk.
Could this theme have championship potential? 👇 #HepMadness2026
5/5 Does the thyroid–liver connection earn your championship pick? 🏆
Submit your bracket by Oct 31:
tourneytopia.com/aasld/hepma…
@LTxJournal @HepCommJournal @aasldtweets #HepMadness2026
4/5 The challenge:
Mechanistic findings in mice don’t establish treatment benefits in people. The HCC study shows an association, and therapeutic implications remain uncertain.
Promising biology—but how far will it go in your bracket?
3/5 The evidence:
• Review: liver THRβ regulates lipid and glucose metabolism.
• Mouse study: T3 restored insulin sensitivity even without hepatocyte THRβ.
• 529,330 Danish patients with thyroid disease: high TSH in hypothyroidism linked to higher HCC incidence (aHR 2.07).
2/5 Why it’s a title contender:
Thyroid hormone influences how the liver handles fat, cholesterol, and glucose.
Understanding these pathways could help identify treatment targets for MASLD—and explain links between thyroid dysfunction and liver outcomes.
⏰ Only 3 days until #HepMadness2026 brackets lock!
16 themes. One champion. 🏆
Have you made your picks yet? Submit your bracket here: tourneytopia.com/aasld/hepma…
Liver Fellow Network retweeted
🎙️ Got a question for the Liver Fellow Podcast?
We’re doing a “Liver Talks” Grab Bag! 🧺
Send us your questions, clinical conundrums, hot takes, fellowship life, career advice, landmark papers, or anything liver-related you’ve been wondering about.
Drop your questions below👇
Liver Fellow Network retweeted
⏰ Only 5 days until #HepMadness2026 brackets lock!
16 themes. One champion. 🏆
Have you made your picks yet? Submit your bracket here: tourneytopia.com/aasld/hepma…
